WellBound opens dialysis center in Santa Rosa
WellBound (Mountain View, California), which said it is the first company focused exclusively on supporting the full spectrum of self-care dialysis therapies, reported the official opening of its fifth specialized self-care dialysis facility in Santa Rosa, California. This “Center of Excellence“ will support nephrologists in providing patients with kidney disease education along with self-care dialysis therapies.
Marc Branson, WellBound's CEO, said, “Together with our physician partners, we are striving to empower patients with kidney disease to take control of their health in order to achieve the benefits [of] self-care dialysis.“
WellBound also reported on a study supporting increased adoption of self-care dialysis therapies, at the annual Dialysis Conference in San Francisco. The study showed that when provided with early dialysis education, many patients chose home-based therapy over traditional in-center hemodialysis.
The company said it analyzed the dialysis therapy selections of 576 patients after they received early education on available treatment options, including conventional in-center hemodialysis, peritoneal dialysis (either CAPD or CCPD), renal transplant, and the various home hemodialysis regimens. Results showed that 42% selected a self-care therapy. Of 206 patients who have completed training, 164 (80%) chose peritoneal dialysis, and 42 (20%) home hemodialysis. Nationally, only 7% of all new dialysis patients select home dialysis as their therapy choice.
New symbol for Micro Imaging
Micro Imaging Technology (MIT; Laguna Hills, California), formerly Electropure, reported that the Nasdaq has issued a new trading symbol for company as a result of approval by company shareholders in October 2005 change its corporate name to Micro Imaging Technology Inc. The new symbol is MMTC.
The company has developed a laser-based technology for rapid microbe detection and identification. The system measures scattered light intensity as individual microbes pass through a laser beam. MIT has demonstrated the ability to detect and immediately identify the microbes Escherichia coli, Listeria, Salmonella Staphylococcus aureus, Shigella and other pathogenic bacteria.
Medivation to trade on AMEX
Medivation (San Francisco) said its common stock has been approved for listing on the American Stock Exchange and was expected to begin trading under the symbol MDV at market open today.
David Hung, MD, president and CEO of Medivation, said: “Based on recent discussions with investors, we believe that an exchange listing may provide Medivation a number of benefits, including increased visibility in the financial community, greater liquidity for our stock and a larger potential investor base that includes those who cannot invest in unlisted securities.“
He added, “These potential benefits are important as we continue to advance our development programs in Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer, and search for promising new technologies to bring into our portfolio.“
Medivation acquires promising medical device and pharmaceutical technologies in late preclinical development, develops those technologies through human first proof-of-efficacy studies (generally the end of Phase II clinical trials), and seeks to sell or partner successful programs with larger pharmaceutical, biotech and device companies for late-stage clinical studies and commercialization.